Abstract:Introduction Chagas disease affects around 8 million individuals globally and about 30% develop cardiac manifestations and, in time, heart failure with reduced ejection fraction (HFrEF). Chagas cardiomyopathy (CC) patients often have a poorer prognosis compared to other causes of HFrEF, owing to a higher rate of ventricular arrhythmias and thromboembolic conditions. Reverse remodelling (RR) has been linked to enhanced mortality and morbidity outcomes in HFrEF due to non-Chagas causes, but the effect of RR on CC prognosis is still unclear. Methods This retrospective study assessed 1043 patients diagnosed with CC via positive serology for Trypanosoma cruzi infection coupled with cardiopathy and ventricular dysfunction [left ventricular ejection fraction (LVEF) < 40%] during the follow-up period from January 2006 to September 2021. The primary outcome measured included overall mortality and heart transplantation in relation to RR status. Propensity score matching was utilised to adjust for confounding factors. Positive reverse remodelling (PRR) was characterised as patients displaying improved LVEF, and negative reverse remodelling (NRR) as those with persistent ventricular dysfunction during follow-up. Results Initially, 221 (21.2%) were categorised as PRR and 822 (78.8%) as NRR. Participants in the PRR group were predominantly female (51.6% versus 41.4%; p < 0.001), older [59 years (53 – 66) versus 56 years (47 – 64); p = 0.007], more prone to hypertension (43.4% versus 35.8%; p = 0.036), and presented with higher initial heart rates [70 bpm (60 – 80) versus 65 bpm (60 – 75); p = 0.002], systolic blood pressure [120 mmHg (110 – 130) versus 110 mmHg (100 – 120); p < 0.001], diastolic blood pressure [80 mmHg (69 – 82) versus 70 mmHg (60 – 80); p < 0.001], and LVEF [30.0% (26.0 – 35.0) versus 29% (25.0 – 34.0); p < 0.001] compared to the NRR group. Moreover, the PRR group had a lower intake of beta-blockers (BB) (76.6% versus 87.0%; p = 0.004), spironolactone (38.5% versus 59.5%; p < 0.001), and triple therapy (30.9% versus 50.4%; p < 0.001). Following propensity score matching, 200 patients remained for the final analysis, with 100 in each group. Cox proportional hazards model analysis revealed PRR as an independent predictor [hazard ratio (HR): 0.367; 95% confidence interval (CI) 0.218 – 0.616; p < 0.001] of mortality from all causes or heart transplantation. The PRR group exhibited a longer event-free survival duration than the NRR group (10.332 years; 95% CI 9.557 – 11.107 versus 7.348 years; 95% CI 6.606 – 8.089; p < 0.001). Discussion This study suggests a positive association between the PRR and increased survival in patients with CHD and HFrEF. Previously published studies didn't demonstrate this association, possibly due to the small number of patients included. Conclusion PRR predicts a better long-term survival free from all-cause mortality and cardiac transplantation in Chagas cardiomyopathy with LVEF < 40%.Kaplan-Meier event-free survival curve

Mortality risk score for patients with Chagas cardiomyopathy and pacemaker

Risk stratifier for sudden cardiac death beyond the left ventricular ejection fraction in Chagas cardiomyopathy

Long-term prognosis and predictors of death in chronic Chagas cardiomyopathy in women and men

Enhancing risk assessment in Chagas cardiomyopathy: Electrophysiology study stratified by Rassi score

Diffuse Myocardial Fibrosis and Cardiomyocyte Diameter Are Associated With Heart Failure Symptoms in Chagas Cardiomyopathy

Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three‐headed monster

Reverse remodelling and clinical outcomes in patients with chagas cardiomyopathy with reduced ejection fraction

Evaluation of patients with implantable cardioverter‐defibrillator in a Latin American tertiary center

Impact of cardiac structure and function on exercise intolerance in Chagas cardiomyopathy: Insights from CPET and echocardiography

Prognostic Value of Preoperative High-Sensitivity C-reactive Protein to Albumin Ratio in Patients with Dilated Cardiomyopathy Receiving Pacemaker Therapy: A Retrospective Two-Center Study in China

Prognóstico de Pacientes Chagásicos e não Chagásicos Submetidos a Implante de Marca-passo e Ressincronizador Cardíaco em Centro Terciário

Impairment of Multiple Mitochondrial Energy Metabolism Pathways in the Heart of Chagas Disease Cardiomyopathy Patients

Clinical features, predictors, and long‐term prognosis of pacing‐induced cardiomyopathy

Predictors of complications and mortality among patients undergoing pacemaker implantation in resource-limited settings: a 10-year retrospective follow-up study

Effectiveness of contemporary risk stratification in patients with hypertrophic cardiomyopathy: a pilot study

Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy

What about chronotropic incompetence in heart failure with mildly reduced ejection fraction? Clinical and prognostic implications from the Metabolic Exercise combined with Cardiac and Kidney Indexes score dataset

Right-Sided Cardiac Thrombosis and Pulmonary Thromboembolism in Chronic Chagas Disease: A Review of Clinical Features and Post-Mortem Examination

Ventricular arrhythmia risk is associated with myocardial scar but not with response to cardiac resynchronization therapy

Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis

Long-term outcomes of patients with apical hypertrophic cardiomyopathy: incorporation of a novel risk score